| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q3 2021 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ICOSAVAX INC | 8 | Q3 2023 | 37.0% |
| VENTYX BIOSCIENCES INC | 8 | Q3 2023 | 37.8% |
| TALARIS THERAPEUTICS INC | 8 | Q3 2023 | 27.1% |
| JASPER THERAPEUTICS INC | 8 | Q3 2023 | 21.1% |
| KEZAR LIFE SCIENCES INC | 8 | Q3 2023 | 12.9% |
| ELEVATION ONCOLOGY INC | 8 | Q3 2023 | 6.6% |
| HILLEVAX INC | 6 | Q3 2023 | 13.9% |
View Qiming U.S. Ventures Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-07-24 |
| 13F-HR | 2023-04-25 |
| 13F-HR | 2023-01-24 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-07-22 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
View Qiming U.S. Ventures Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.